Research Topics
| Xiaoping ZhangSummaryAffiliation: F. Hoffmann-La Roche Ltd Publications
| Collaborators
|
Detail Information
Publications
Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment dispositionXiaoping Zhang
Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
Clin Pharmacol Ther 72:10-9. 2002....- Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patientsXiaoping Zhang
Department of Clinical Pharmacology, Roche, Nutley, NJ 07110, USA
Clin Pharmacol Ther 75:558-68. 2004..This study investigated whether enfuvirtide can influence the activities of cytochrome P450 (CYP) enzymes in HIV-1-infected patients... - Population pharmacokinetics of enfuvirtide in HIV-1-infected pediatric patients over 48 weeks of treatmentXiaoping Zhang
Hoffmann La Roche, Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
J Clin Pharmacol 47:510-7. 2007..105 h(-1), respectively. The final model was CL/F (L/h) = 1.31 . (body weight/33 [kg])(0.721). Age did not affect enfuvirtide exposure. These results confirm the appropriateness of body weight-based pediatric enfuvirtide dosing... 
Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participantsXiaoping Zhang
Hoffmann La Roche, Inc, Nutley, NJ, USA
J Clin Pharmacol 52:520-9. 2012..PubMed search and Roche postmarketing data did not reveal publications or reports directly presenting the effect of saquinavir on QT/QTc or causing torsade de pointes...- Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtideIndravadan H Patel
Roche, Nutley, New Jersey 07110, USA
Clin Pharmacokinet 44:175-86. 2005..In HIV-1-infected paediatric patients, subcutaneous dosages based on bodyweight (2 mg/kg twice daily) produce pharmacokinetics broadly similar to those observed in adults administered 90 mg twice daily... 
Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjectsXiaoping Zhang
Department of Clinical Pharmacology, Hoffmann La Roche Inc, Nutley, NJ 07110, USA
Antimicrob Agents Chemother 55:680-7. 2011..The AUC(0-96) of rifabutin was not affected, and C(max) increased by 68%. Monitoring of neutropenia and liver enzyme levels is recommended for patients receiving rifabutin with saquinavir-ritonavir BID...- A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritisXiaoping Zhang
Department of Clinical Pharmacology, Hoffmann La Roche Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
J Clin Pharmacol 50:1031-8. 2010..The results of this study suggest that dose adjustments for either drug are not necessary when concomitantly administered and that pamapimod can decrease pharmacodynamic markers of disease activity... - Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritisXiaoping Zhang
Department of Clinical Pharmacology, Hoffmann La Roche Inc, 340 Kingsland Street, Nutley, NJ 07110, USA
Expert Rev Clin Pharmacol 4:539-58. 2011..Tocilizumab exposures are not affected by common concomitant medications in RA patients, but decreased IL-6 activity resulted in increased CYP3A4 activity and hence decreased exposures of CYP3A4 substrates... - Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods testedXiaoping Zhang
Department of Clinical Pharmacology, Hoffman La Roche Inc, Nutley, NJ 07110, USA
J Clin Pharmacol 49:534-9. 2009..60 ms for day -1 time-matched baseline ECGs, and 1.65 ms for no baseline correction. Predose baseline methods (3 or 1 triplicate ECGs) are superior to the day -1 time-matched baseline correction or without baseline correction... - Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagementHong C Shen
Merck Research Laboratories, Merck and Co, Inc, Rahway, NJ 07065 0900, USA
J Med Chem 52:5009-12. 2009..With minimal off-target activity and a good PK profile, the benchmark 2d exhibited remarkable in vitro and ex vivo target engagement. The eutomer entA-2d also elicited vasodilation effect in rat mesenteric artery... - Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patientsDiane R Mould
Projections Research Inc, Phoenixville, PA, USA
Clin Pharmacol Ther 77:515-28. 2005..CONCLUSIONS: Body weight and gender affected enfuvirtide clearance, but changes in exposure did not affect efficacy or safety. Efficacy reached a plateau at the 90-mg twice-daily dosage in the exposure-response curve... - Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patientsKiat Ruxrungtham
Thai Red Cross AIDS Research Centre, Rama 4 Road, Bangkok 10330, Thailand
J Clin Pharmacol 44:793-803. 2004..Thus, no dosage adjustments are warranted when enfuvirtide is coadministered with low-dose ritonavir or saquinavir boosted with a low dose of ritonavir... - Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtideMark Alastair Boyd
HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT, The Thai Red Cross AIDS Research Centre, Pathumwan, Bankok, Thailand
J Clin Pharmacol 43:1382-91. 2003..There were no unexpected effects of rifampicin on the short-term antiviral effect or safety of the administered antiretroviral treatment. The pharmacokinetics of enfuvirtide are not induced by a 10-day pretreatment with rifampicin... - Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patientsJacob P Lalezari
Quest Clinical Research, 2300 Sutter Street, Suite 202, San Francisco, CA 94115, USA
J Clin Virol 28:217-22. 2003..Enfuvirtide is the first in a new class of antiretrovirals (ARVs), the fusion inhibitors, and the first ARV to be administered by subcutaneous (s.c.) injection... - Optimizing size and copy number for PEG-fMLF (N-formyl-methionyl-leucyl-phenylalanine) nanocarrier uptake by macrophagesLi Wan
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, New Jersey 08854, USA
Bioconjug Chem 19:28-38. 2008..The convenience, flexibility and possible limitations of this nanocarrier approach are discussed... - Lysine 144, a ubiquitin attachment site in HIV-1 Nef, is required for Nef-mediated CD4 down-regulationYong Jiu Jin
Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
J Immunol 180:7878-86. 2008..These data suggest that ubiquitination of Nef, particularly diubiquitination of the lysine 144, is necessary for Nef-mediated CD4 down-regulation... - Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cellsXiaoping Zhang
Department of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Clin Cancer Res 13:7181-90. 2007..In this study, we investigated whether synthetic induction of c-Fos/AP-1 by 12-O-tetradecanoylphorbol-13-acetate (TPA) converts the phenotype of TRAIL-resistant prostate cancer cells to a TRAIL-sensitive phenotype in vitro and in vivo...